Jan. 1, 2017, 9:07 p.m.
Mirimus and Charles River Announce Partnership on CRISPR/Cas9 In Vivo Model Creation Services
Mirimus, Inc. and Charles River Laboratories International, Inc. together expand their mouse engineering capabilities through a strategic partnership. Mirimus, a leader in the creation of RNA interference technology and its use in animal models, has chosen Charles River Laboratories for production of their RNAi mouse models to service their clients with VAF/Elite® quarantine-free animals and provide a full range of drug discovery services globally.
In parallel, Charles River Laboratories recently launched their full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. With this technology, Charles River will be able to develop more custom translational research models that will ultimately improve the
efficiency and effectiveness of the drug discovery process.
"The combination of Mirimus’ RNA interference and CRISPR/Cas9 genome engineering expertise fused with Charles River’s in vivo model creation services creates a powerful platform for custom model generation,” said Prem K. Premsrirut, MD, PhD, Founder and Chief Executive Officer of Mirimus. "Charles River’s licensing arrangement with the Broad Institute of MIT and Harvard will allow us to rapidly develop novel mouse models, combining the strengths of both CRISPR/Cas9 genome engineering and RNAi technologies, a big step forward for our clients."
"Utilizing the CRISPR/Cas9 platform, Charles River clients can work with a single provider for both the in vivo and in vitro phases of their research,” said Dr. Iva Morse, Corporate Vice President, Chief Scientific Officer, Global Research Models and Services at Charles River. “Working with us, clients can generate custom cell lines for early, exploratory discovery research, as well as in vivo pharmacology models, produce those models, and then use our Discovery Services offering to place those models in in vivo studies."
Clients engaged in drug discovery can tap into Mirimus experts in creation of RNAi mouse models for early preclinical toxicity assessment and gene target prioritization, to guide early no-go decisions and focus on targets with a promising safety profile. In addition, with this partnership, all clients have access to chemistry, biology and pharmacology experts through the Discovery Services team at Charles River for innovative support and guidance in small molecule drug development expertise across all therapeutic areas.
The natural synergy between Mirimus’ molecular biology and Charles River’s embryology capabilities allows Mirimus to deliver study-ready cohorts to meet client project needs and timelines. Charles River’s successful track record in embryology, coupled with their global network of secure breeding facilities and delivery platforms, allows clients to receive their unique genetically engineered models as needed, with no quarantine period.